Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use

Mostrar otras versiones (1)

Levosimendan was first approved for clinic use in 2000, when authorisation was granted by Swedish regulatory authorities for the haemodynamic stabilisation of patients with acutely decompensated chronic heart failure. In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, Zoltán, Agostoni, Piergiuseppe, Alvarez, Julian, Bettex, Dominique, Bouchez, Stefan, Brito, Dulce, Černý, Vladimir, Comin-Colet, Josep, Crespo-Leiro, Marisa G, Delgado, Juan F, Édes, Istvan, Eremenko, Alexander A, Farmakis, Dimitrios, Fedele, Francesco, Fonseca, Cândida, Fruhwald, Sonja, Girardis, Massimo, Guarracino, Fabio, Harjola, Veli-Pekka, Heringlake, Matthias, Herpain, Antoine, Heunks, Leo MA, Husebye, Tryggve, Ivancan, Višnja, Karason, Kristjan, Kaul, Sundeep, Kivikko, Matti, Kubica, Janek, Masip, Josep, Matskeplishvili, Simon, Mebazaa, Alexandre, Nieminen, Markku S, Oliva, Fabrizio, Papp, Julius-Gyula, Parissis, John, Parkhomenko, Alexander, Põder, Pentti, Pölzl, Gerhard, Reinecke, Alexander, Ricksten, Sven-Erik, Riha, Hynek, Rudiger, Alain, Sarapohja, Toni, Schwinger, Robert HG, Toller, Wolfgang, Tritapepe, Luigi, Tschöpe, Carsten, Wikström, Gerhard, von Lewinski, Dirk, Vrtovec, Bojan, Pollesello, Piero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2020
Materias:
Pharmacological Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374352/
https://www.ncbi.nlm.nih.gov/pubmed/32714567
http://dx.doi.org/10.15420/cfr.2020.03

Ejemplares similares

Ejemplares similares